Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care

By Reuters News

- Sanofi SA SASY.PA:

  • SANOFI AND PCPA SIGN LETTER OF INTENT FOR DUPIXENT® ACROSS FOUR INDICATIONS IN DERMATOLOGY AND RESPIRATORY CARE

  • TO SUPPORT PATIENT ACCESS TO DUPIXENT VIA PUBLIC DRUG PLANS IN CANADA

Further company coverage: SASY.PA

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk